Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zn-Telomir in Advanced or Metastatic Triple-Negative Breast Cancer
NCT07581314Phase 2Not yet recruiting
- Sponsor
- Telomir Pharmaceuticals, Inc.
- Start
- Oct 2026
- Primary completion
- May 2027
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of Telomir-Zn in triple-negative breast cancer (TNBC), sponsored by Telomir Pharmaceuticals, Inc.. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
Telomir-Zn
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT07581314.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07581314.